EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study

Mi-Hyun Kim iD, Min Ki Lee, Ji Eun Park, Sun Hyo Park iD, Tae Won Jang, Chi Young Jung, Insu Kim iD, Seong Hoon Yoon, June Hong Ahn iD, Hyun-Kyung Lee, Jin Han Park, Sun Ha Choi und 1 weitere

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70083 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Mi-Hyun Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yuhan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The clinical application of lazertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has extended to the treatment of EGFR‐mutant non‐small‐cell lung cancer (NSCLC); however, the effects of its dose modification on its efficacy and safety have not yet been adequately established.

Methods

This prospective, multicenter, observational cohort study aims to evaluate the clinical implications of adjusting the lazertinib dose. Patients will be categorized into two groups based on the lazertinib dose administered during the initial 12 weeks of treatment in routine clinical practice: 160 and 240 mg groups. The primary endpoints are progression‐free survival in the 160 mg group and identifying risk factors associated with dose modification during the 12‐week period.

Discussion

The findings from the present study will provide real‐world insights into the clinical factors leading to lazertinib dose adjustments and deepen our understanding of the efficacy and safety of lazertinib in patients with NSCLC. Our research will contribute toward optimizing medical strategies for NSCLC treatment and aid clinicians in making accurate clinical decisions regarding dose modifications in routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungProtein Kinase InhibitorsHumansProspective StudiesErbB ReceptorsFemaleMaleMiddle AgedAged

Stichwörter der Autor:innen

dose modificationepidermal growth factor receptorlazertinibtreatment outcome

Substanzen

EGFR protein, humanErbB ReceptorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Division of Pulmonology, Respiratory Center, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea.
  • Department of Internal Medicine, Kosin University Medical College, Busan, Republic of Korea.
  • Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea.

ORCID-Profile: Mi-Hyun Kim, Sun Hyo Park, Insu Kim, June Hong Ahn, Jung Seop Eom

Förderung

  • Yuhan

Zitieren

APA

Kim, M. H., Lee, M. K., Park, J. E., Park, S. H., Jang, T. W., Jung, C. Y., Kim, I., Yoon, S. H., Ahn, J. H., Lee, H. K., Park, J. H., Choi, S. H., & Eom, J. S. (2025). Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70083

Vancouver

Kim MH, Lee MK, Park JE, Park SH, Jang TW, Jung CY, et al. Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70083

BibTeX
@article{Kim2025,
  author = {Kim, Mi-Hyun and Lee, Min Ki and Park, Ji Eun and Park, Sun Hyo and Jang, Tae Won and Jung, Chi Young and Kim, Insu and Yoon, Seong Hoon and Ahn, June Hong and Lee, Hyun-Kyung and Park, Jin Han and Choi, Sun Ha and Eom, Jung Seop},
  title = {Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR ‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70083}
}
Kostenlos starten →